114 related articles for article (PubMed ID: 3136697)
1. [Experimental and clinical study of interactions between fluorinated pyrimidine derivatives and anticoagulants].
Ogawa J; Inoue H; Koide S; Kawada S; Shohtsu A
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2265-71. PubMed ID: 3136697
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
[TBL] [Abstract][Full Text] [Related]
3. [Clinical results of UFT plus anticoagulants as a postoperative adjuvant in lung cancer patients].
Ogawa J; Inoue H; Koide S; Kawada S; Shohtsu A
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2273-7. PubMed ID: 3136698
[TBL] [Abstract][Full Text] [Related]
4. Dipyridamole augments the antitumor effects of fluorinated pyrimidines.
Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K
Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156
[TBL] [Abstract][Full Text] [Related]
5. Interactions between UFT and anticoagulants in lung cancer patients.
Ogawa J; Inoue H; Tsurumi T; Inoue H; Koide S; Kawada S; Shohtsu A
Jpn J Surg; 1988 May; 18(3):243-51. PubMed ID: 3136266
[TBL] [Abstract][Full Text] [Related]
6. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
7. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
Sekiguchi I; Suzuki M; Tamada T; Nishida M
Gan To Kagaku Ryoho; 1985 May; 12(5):1094-8. PubMed ID: 3922312
[TBL] [Abstract][Full Text] [Related]
8. [Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region].
Ohyama K; Koike D; Odake Y; Takiyama Y; Saitoh T; Kagaya T; Takebe T; Ishii K
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2168-74. PubMed ID: 6307180
[TBL] [Abstract][Full Text] [Related]
9. [Interactions between UFT and anticoagulants].
Ogawa J; Inoue H; Shohtsu A
Nihon Geka Gakkai Zasshi; 1987 Jun; 88(6):790. PubMed ID: 3114615
[No Abstract] [Full Text] [Related]
10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
11. [Serum and tissue concentrations of UFT in patients with lung cancer].
Aota M; Nakayama S; Yokomise H; Jinno K; Daitoh N
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3046-55. PubMed ID: 3094458
[TBL] [Abstract][Full Text] [Related]
12. [Level of 5-FU in tumor tissues of the patients with head and neck malignant tumors after oral administration of UFT].
Kusama M; Utsunomiya Y; Ono T; Nagura H; Enomoto S
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1796-802. PubMed ID: 6411004
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
[TBL] [Abstract][Full Text] [Related]
14. [5-FU concentration in the tissues (tumor and lymph node) of breast cancer patients given preoperative administration of UFT and FT].
Koida T; Kimura M
Gan To Kagaku Ryoho; 1985 May; 12(5):1147-51. PubMed ID: 3922313
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Fujita F; Fujita M; Inaba H; Taguchi T
Gan To Kagaku Ryoho; 1993 Feb; 20(2):223-8. PubMed ID: 8434959
[TBL] [Abstract][Full Text] [Related]
16. [UFT concentration in various tissues from cancer patients].
Kasai Y; Nakanishi Y; Nishi H; Nishindai H; Yoshimoto M; Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2130-8. PubMed ID: 6414381
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
18. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
19. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
[TBL] [Abstract][Full Text] [Related]
20. [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Takahashi N; Nitta A; Saitou T; Mori Y; Kunii Y; Kikuchi K
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2319-23. PubMed ID: 3136701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
